Kiora Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

In computing diluted loss per share, no effect has been given to the common shares issuable upon conversion or exercise of the following dilutive securities as the Company’s net loss would make the effect anti-dilutive.


	March 31, 2015 (unaudited)		December 31, 2014
Series A convertible preferred stock				625,895
Series B convertible preferred stock (including 525,004 shares from conversion of non-controlling interest)				1,262,651
Series C convertible preferred stock (including 187,183 shares from conversion of non-controlling interest)				537,233
Series D convertible preferred stock (including 358,146 shares from conversion of non-controlling interest)				2,145,810
Common stock warrants		637,980		18,176
Employee stock options		1,156,090		752,372
Total common shares issuable		1,794,070		5,342,137

	Year Ended December 31,
	2014		2013
Series A convertible preferred stock		625,895		625,895
Series B convertible preferred stock (including 525,004 shares from conversion of non-controlling interest)		1,262,651		1,262,651
Series C convertible preferred stock (including 187,183 shares from conversion of non-controlling interest)		537,233		537,233
Series D convertible preferred stock (including 358,146 shares from conversion of non-controlling interest)		2,145,810		2,145,810
Common stock warrants		18,176		18,176
Employee stock options		752,372		762,944
Total common shares issuable		5,342,137		5,352,709

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table represents the fair value of the warrant liability measured at fair value on a recurring basis:


	Level 1	Level 2	Level 3		Total
As of December 31, 2014
Non-current liabilities:
Warrant liability	$	$	$	303,102	$	303,102

The following table represents the fair value of the warrant liability measured at fair value on a recurring basis:

	Level 1	Level 2	Level 3		Total
As of December 31, 2014
Non-current liabilities:
Warrant liability	$	$	$	303,102	$	303,102

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following are the changes in the level 3 warrant liability for the three months ended March 31, 2015:


Beginning balance at December 31, 2014	$	303,102
Settlement of warrant liability		(79,930	)
Change in fair value		(223,172	)
Ending balance at March 31, 2015	$	0

The following are the changes in the level 3 warrant liability for the year ended December 31, 2014:

Beginning balance	$	0
Issuance of warrants		1,398,384
Change in fair value		(1,095,282	)
Ending balance	$	303,102

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details